argus retinal prosthesis also known bionic eye electronic retinal implant manufactured american company second sight medical products used visual prosthesis improve vision people severe cases retinitis pigmentosa argus ii version system approved marketing european union march received approval us february humanitarian device exemption argus ii system costs excluding cost implantation surgery training learn use device second sight ipo listed production development prosthesis discontinued taken company cortigent argus ii specifically designed treat people retinitis device approved data singlearm clinical trial enrolled thirty people severe retinitis pigmentosa longest followup trial subject people trial received implant one eye tests conducted device switched switched device switched subjects improvements ability see higher logmar scale improvements ranged logmar equivalent reading subjects better able identify white square black computer screen able determine direction white bar moved across black computer screen device switched able accurately walk door feet away opposed device switched change perception among thirty subjects clinical trial nine serious adverse events recorded including lower normal intraocular pressure erosion conjunctiva reopening surgical wound inflammation inside eye retinal also risk bacterial infection implanted cables connect implant signal implantation procedure takes several hours person receiving implant general anaesthesia surgeon removes vitreous humor membranes retina implant placed implant attached surface retina tack cables connecting implant processor run pars plana region near iris sclera argus implants primary external element digital camera mounted eyeglass frames obtains images users surroundings signals camera transmitted wirelessly computerised image processor processor turn connected cables implant surgically implanted surface persons retina tacked place implant consists electrodes microns resolution dot dot rectangular grid image produced array electrode enabled persons vision low relative normal visual acuity allows visual detection edges large areas high contrast door frames sidewalks give individual capability navigate environment implants manufacturer second sight medical products founded sylmar california alfred mann samuel williams gunnar williams investor cochlear implant company operated mann approached mann founding company develop similar product eye mann called meeting two robert greenberg worked manns greenberg previously worked retinal prosthetics graduate student johns hopkins university wrote business plan appointed ceo new company greenberg led company ceo chairman board first version prosthesis argus clinically tested six people starting second version argus ii designed smaller easier implant coinvented mark humayun usc eye institute involved clinical testing argus argus ii first tested mexico clinical trial conducted medical centers across europe united argus ii received approval commercial use european union march february fda approved argus ii humanitarian device exemption authorizing use people us per argus ii initially available limited number clinics france germany italy netherlands united kingdom saudi arabia eu market price argus ii launched united states february second sight announced would priced around excluding cost surgery usage august second sight announced reimbursement payments approved argus ii blind medicare recipients united trial england funded nhs england ten patients began second sight stopped providing technical support argus well successor device argus ii brain implant orion investigation ieee spectrum revealed users risk cases already experienced return httpsenwikipediaorgwikiargusretinalprosthesis